REGN up +2.42% percent Today $REGN High is at 404.77 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
REGN up +2.42% percent Today $REGN High is at 404.77 and the Low 395.20 with current volume of 167,953.

Recent News posted below.

Regeneron Pharmaceuticals REGN other info.
http://investorshangout.com/Regeneron-Pharmac...EGN-55275/

REGN Regeneron Pharmaceuticals Recent Headline News

Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 41.04 (+0.99), REGN: 405.48 (+10.28), NVS: 94.42 (+0.47)

Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST

BIIB: 307.60 (+2.17), VRTX: 111.52 (+0.18), GILD: 101.35 (-0.71), ALXN: 190.44 (+1.68), AMGN: 159.70 (+2.02), IBB: 291.41 (+3.24), REGN: 405.48 (+10.28), CELG: 105.30 (+1.25)

Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 101.35 (-0.71), AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)

Meet 5 U.S. Techs, Biotechs With Strong Fundamentals
at Investor's Business Daily - Thu Nov 13, 7:02AM CST
With the market in confirmed uptrend and stock indices approaching new highs, focusing on companies with the best fundamentals, such as Regeneron Pharmaceuticals, is a ticket to winners that are likely to outperform the market. Today's Screen Of The...
JPM: 60.12 (-0.16), LNKD: 225.19 (-8.70), SFY: 6.32 (-0.21), CYBR: 43.50 (-0.87), FB: 75.17 (+0.29), ALXN: 190.44 (+1.68), TGT: 67.58 (-0.55), DATA: 85.52 (+0.69), TWTR: 40.90 (-0.95), PANW: 111.46 (+0.68), REGN: 405.48 (+10.28)

Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 212.98 (+14.33), ABBV: 64.94 (+0.94), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 111.52 (+0.18), GILD: 101.36 (-0.70), ACHN: 13.91 (-0.06), DNDN: 0.12 (+0.01), AMGN: 159.70 (+2.02), ABBV: 64.94 (+0.94), REGN: 405.48 (+10.28)

Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.16 (+0.05), DHI: 24.47 (+0.09), AMZN: 321.81 (-6.01), TSLA: 256.24 (-2.44), KR: 58.21 (+0.50), SWY: 34.83 (-0.02), CLX: 100.31 (+0.19), XOM: 94.46 (-0.63), FCAU: 12.43 (+0.03), INO: 9.92 (-1.08), WHR: 175.67 (+2.40), T: 35.76 (-0.14), ISIS: 49.43 (+0.42), VALE: 8.85 (-0.02), EOG: 96.51 (-1.65), HAWK: 36.56 (+0.09), SHW: 240.29 (+0.64), VZ: 51.32 (-0.18), TOL: 33.69 (-0.03), REGN: 405.48 (+10.28), KELYA: 15.42 (unch), BABA: 114.64 (-0.46)

Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.47 (+0.09), TSLA: 256.24 (-2.44), AMZN: 321.81 (-6.01), CY: 9.97 (-0.07), XOM: 94.46 (-0.63), KEX: 103.40 (-1.35), LRN: 12.83 (-0.26), BWLD: 161.22 (-1.45), ADBE: 70.72 (-0.70), GTLS: 42.46 (-0.56), TWX: 79.96 (+0.21), WHR: 175.67 (+2.40), T: 35.76 (-0.14), LYB: 87.19 (-1.14), ISIS: 49.43 (+0.42), CMG: 663.14 (-6.66), EOG: 96.51 (-1.65), HAWK: 36.56 (+0.09), SHW: 240.29 (+0.64), VZ: 51.32 (-0.18), DOW: 50.96 (-0.41), REGN: 405.48 (+10.28), KELYA: 15.42 (unch), CBS: 53.26 (-0.15)

Asthma treatment passes trial
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring asthma attacks. Based...
SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)

Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 386.96 (+0.92), YHOO: 51.36 (-0.39), AMZN: 321.80 (-6.02), BIIB: 307.60 (+2.17), VRTX: 111.42 (+0.08), FEYE: 33.28 (-0.52), LNKD: 225.19 (-8.70), EBAY: 54.72 (+0.36), GILD: 101.37 (-0.69), AMGN: 159.70 (+2.02), ABBV: 64.95 (+0.95), REGN: 405.48 (+10.28), CELG: 105.30 (+1.25)

Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN)
at The Street - Tue Nov 11, 8:51AM CST
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
REGN: 405.48 (+10.28)

Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST

MRK: 59.85 (+0.78), AZN: 71.98 (-0.87), AMGN: 159.70 (+2.02), TEVA: 57.86 (+0.79), THRX: 13.32 (+0.09), GSK: 45.88 (+0.14), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28), NVS: 94.42 (+0.47)

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.36 (+0.06), SNY: 47.17 (+0.49), REGN: 405.48 (+10.28)

After Yesterday's Rally of 2.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:06PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $376.54 to a high of $386.86. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $381.00 on volume of 539,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 405.48 (+10.28)

Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
REGN: 405.48 (+10.28)

3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.15 (-0.10), SNY: 47.17 (+0.49), GNW: 9.36 (-0.05), REGN: 405.48 (+10.28)

Regeneron updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:09AM CST

REGN: 405.48 (+10.28)

Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST

AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.18 (+9.98)

Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 90.68 (+0.56), AMGN: 159.70 (+2.02), SNY: 47.17 (+0.49), REGN: 405.18 (+9.98)

20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 307.60 (+2.17), MNST: 109.10 (+1.18), ATI: 32.38 (-0.47), MON: 118.91 (-0.06), GMCR: 154.92 (+0.65), VMC: 66.10 (-0.21), EMR: 63.47 (-0.15), WDC: 97.51 (-0.90), VRSN: 60.68 (+0.01), URBN: 30.91 (+0.06), FSLR: 47.77 (-0.72), DE: 86.08 (-1.44), EXPE: 87.69 (-0.24), FLR: 63.77 (-0.93), FLS: 65.80 (-0.33), X: 35.55 (-0.69), ROK: 109.50 (-0.62), REGN: 405.18 (+9.98), MA: 84.03 (-0.02)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 0

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 96

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 37

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 22

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 13

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 56

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading

Top 5 Most Recently Viewed Articles

SK Chemicals Delivers Sustainable Innovation at ECS 2025

Updated Category News Views 484

SK Chemicals at the European Coatings Show 2025 SK chemicals has proudly participated in the European Coatings Show (ECS) 2025, marking a significant moment for the company as it engages in marketing its innovative materials. This event is known for attracting key players in the coatings and paint sector, and this year was no exception, with over 1,000 exhibitors and more...

Continue Reading
Analyzing TJX Companies' Increased Short Interest Trends

Updated Category News Views 230

Understanding the Rise in TJX Companies' Short Interest The short interest for TJX Companies (NYSE: TJX) has seen a significant uptick, now standing at 14.55 million shares sold short, which constitutes 1.29% of its float. This marks a 21.7% increase since the prior reporting period. Given the current trading volume, traders would require approximately 2.49 days to cover...

Continue Reading
IGT Expands Collaboration with La Française des Jeux for Instant Tickets

Updated Category News Views 69

IGT Expands Collaboration with La Française des Jeux Company to deliver top-performing instant ticket games to one of the world's largest lotteries International Game Technology PLC (NYSE: IGT) has officially entered a three-year partnership with La Française des Jeux (FDJ), the esteemed operator of the French National Lottery. This significant agreement follows a...

Continue Reading
Archer Expands Footprint with New Manufacturing Facility Opening

Updated Category News Views 267

Archer Expands Footprint with New Manufacturing Facility Opening New state-of-the-art facility doubles manufacturing capacity and adds more than 200 local jobs Archer, one of the fastest-growing meat snack brands in the U.S., is celebrating a significant milestone with the grand opening of its new manufacturing facility. This latest addition in Vernon, California,...

Continue Reading
Bumble Faces Downgrade from KeyBanc Amid Revenue Concerns

Updated Category News Views 309

Bumble Inc (NASDAQ: BMBL) took a hit when KeyBanc downgraded its rating from 'Overweight' to 'Sector Weight', shaking the confidence of many investors. The downgrade was more than just a simple reassessment; it became a catalyst for a stock value decline in premarket trading that had traders watching their screens with bated breath. KeyBanc Downgrade: A Harbinger of...

Continue Reading